
The $5 Billion Question: What Isomorphic's Round Says About AI Drug Discovery, Pharma Partnerships and the Road to Phase 1
Dr. Dereck Mush, MD, MBAMass General Brigham spinout building AI models that make medicine computable.
Aevius is a clinical intelligence company and Mass General Brigham spinout, founded to make medicine computable. It develops AI models that learn from structured, unstructured and specialty multimodal medical data, including medical records and imaging, to create a refreshable multimodal patient representation that can be updated as new information arrives. Organizations can use it to forecast outcomes, find clinically similar patients, identify and stratify populations and monitor change over time. Aevius is bringing the technology to health systems, payers and life sciences companies. On November 17, 2026, it launched with $22 million in funding led by Insight Partners.
Co-founder and CEO
Co-founder and CTO
Scientific Co-Founder
Scientific Co-Founder
Chief Commercial Officer
Chair, Scientific Advisory Board
Founding Engineer
How Aevius got here, step by step.
17 November 2026
Aevius launched with $22 million in funding led by Insight Partners to support model and product development, team expansion across engineering, clinical and commercial functions, and commercial deployment.
17 November 2026
Aevius Launches with $22 Million in Funding to Make Medicine Computable17 November 2026
$22 million launch funding18 November 2026
Rowland Pettit, Co-founder and CEO18 November 2026
Ming Yang (Max) Lu, Co-founder and CTO18 November 2026
Faisal Mahmood, Scientific Co-Founder18 November 2026
Long Phi Le, Scientific Co-Founder
Dr. Dereck Mush, MD, MBAMentions Aevius
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: